Effectiveness and Respiratory Adverse Events Following Inactivated and mRNA COVID-19 Vaccines in Patients with COPD and Asthma: A Chinese Population-Based Study
ConclusionsAmong people with COPD and asthma, the COVID-19 vaccines CoronaVac and BNT162b2 did not increase severe exacerbations and achieved moderate-to-high effectiveness against COVID-related outcomes. COVID-19 vaccination remains essential and should be encouraged to protect this vulnerable population in future epidemic waves.
Source: Drug Safety - Category: Drugs & Pharmacology Source Type: research
More News: Asthma | China Health | Chronic Obstructive Pulmonary | Coronavirus | Covid Vaccine | COVID-19 | Drugs & Pharmacology | Epidemics | Epidemiology | Health Management | Hong Kong Health | Intensive Care | Respiratory Medicine | Study | Vaccines